These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20658898)

  • 1. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice.
    Nichols GA; Conner C; Brown JB
    Curr Med Res Opin; 2010 Sep; 26(9):2127-35. PubMed ID: 20658898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin use in decompensated heart failure.
    Boyd A; Nawarskas J
    Cardiol Rev; 2008; 16(5):269-72. PubMed ID: 18708828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin discontinuation rate among patients with type-2 diabetes mellitus in Basrah, Iraq.
    Mansour AA; Habib OS
    Saudi Med J; 2007 Dec; 28(12):1919-21. PubMed ID: 18060234
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice.
    Almirall J; Bricullé M; Gonzalez-Clemente JM
    Nephrol Dial Transplant; 2008 Jul; 23(7):2436-8. PubMed ID: 18388117
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin/metformin (Janumet) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).
    Kogut SJ; Andrade SE; Willey C; Larrat EP
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):591-8. PubMed ID: 15362081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus]].
    Rahn A
    Med Klin (Munich); 2002 Jul; 97(7):435; author reply 436. PubMed ID: 12168485
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes.
    Florez H; Luo J; Castillo-Florez S; Mitsi G; Hanna J; Tamariz L; Palacio A; Nagendran S; Hagan M
    Postgrad Med; 2010 Mar; 122(2):112-20. PubMed ID: 20203462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of risk determinants for metformin-associated lactic acidosis and metformin utilization in the study of health in pomerania.
    Runge S; Alte D; Baumeister SE; Völzke H
    Horm Metab Res; 2008 Jul; 40(7):491-7. PubMed ID: 18401838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin plus glyburide combination as therapy in failure to monotherapy in type 2 diabetic patients: one month follow-up.
    Medina Santillán R; Reyes-García G; Mateos-García E
    Proc West Pharmacol Soc; 2002; 45():139-40. PubMed ID: 12434559
    [No Abstract]   [Full Text] [Related]  

  • 16. Metformin use in patients with diabetes mellitus and heart failure: friend or foe?
    Giamouzis G; Triposkiadis F; Butler J
    J Card Fail; 2010 Mar; 16(3):207-10. PubMed ID: 20206894
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
    [No Abstract]   [Full Text] [Related]  

  • 18. Does glucose infusion exacerbate metformin-associated lactate acidosis? A case report.
    Brouwers MC; Schaper N; Keeris L
    Diabetes Res Clin Pract; 2009 Jul; 85(1):e1-3. PubMed ID: 19427052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin in type 2 diabetes.
    Fox GN
    J Fam Pract; 2004 Nov; 53(11):900. PubMed ID: 15527727
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.